Ishara Investments LP
13F Reported Value
ⓘ$105.6M
incl. option notional
Equity Holdings
ⓘ$99.0M
Option Notional
ⓘ$6.6M
$6.6M puts / $0 calls
Holdings
37
Latest Filing
2026-03-31
Filing Quarter
Q1 2026
Portfolio Overview
Ishara Investments LP disclosed 37 positions worth $105.6M in its Form 13F-HR for Q1 2026 — $99.0M in common stock plus $6.6M of put/call option positions (reported at underlying notional value, not premium at risk), led by $PRAX (Praxis Precision Medicines, Inc.) at 7.3% of the equity portfolio, followed by $AXSM and $PRAX. During the quarter the fund opened 18 new positions and exited 19 — including a new stake in $AXSM and a full exit from $NUVB. The portfolio is most concentrated in Healthcare (100.0% of disclosed assets). All figures are sourced directly from Ishara Investments LP’s Form 13F-HR filing with the SEC under CIK 2111609.
Sector Allocation
AUM History
Top Equity Holdings by Value
Option Positions
13F rules report options at the value of the underlying shares (notional) — not the premium paid or capital at risk. Shown separately from the equity sleeve above.
Quarterly Activity — Q1 2026
Click any card to unlockTop Holdings
- $7.3M22,550 sh
- 36.6#2,091
Quality
$6.9M41,000 sh - $6.6M20,500 sh
- 45.5
Quality
$5.9M1,025,000 sh - 25.9
Quality
$5.6M276,750 sh - 44.2
Quality
$5.3M369,000 sh - 74.1
Quality
$4.6M82,000 sh - 40.8
Quality
$4.3M820,000 sh - 31.0
Quality
$3.7M174,250 sh - 74.4
Quality
$3.5M55,350 sh
| Company | Quality | Value | Shares |
|---|---|---|---|
 Praxis Precision Medicines, Inc.$PRAX | — | $7.3M | 22,550 |
 Axsome Therapeutics, Inc.$AXSM | 36.6#2,091 | $6.9M | 41,000 |
| Praxis Precision Medicines, Inc.$PRAXPUT | — | $6.6M | 20,500 |
 Xeris Biopharma Holdings, Inc.$XERS | 45.5 | $5.9M | 1,025,000 |
 KalVista Pharmaceuticals, Inc.$KALV | 25.9 | $5.6M | 276,750 |
 AMICUS THERAPEUTICS, INC.$FOLD | 44.2 | $5.3M | 369,000 |
 BIOMARIN PHARMACEUTICAL INC$BMRN | 74.1 | $4.6M | 82,000 |
 Verastem, Inc.$VSTM | 40.8 | $4.3M | 820,000 |
 Ultragenyx Pharmaceutical Inc.$RARE | 31.0 | $3.7M | 174,250 |
 ARROWHEAD PHARMACEUTICALS, INC.$ARWR | 74.4 | $3.5M | 55,350 |
Unlock AI quality scores for every holding
32-signal composite ranking on each of Ishara Investments LP's 37 positions.
Showing top 10 of 37 holdings.
Sector Allocation
Healthcare
$99.0M
Full Holdings — Ishara Investments LP (Q1 2026)
All 37 disclosed positions from the latest Form 13F-HR, with quarter-over-quarter share changes and 13F Pro quality scores. Sourced from SEC EDGAR.
| # | Ticker | Company | Value | Weight | QoQ | Quality |
|---|---|---|---|---|---|---|
| 1 | $PRAX | Praxis Precision Medicines, Inc. | $7.3M | 7.3% | -44% | — |
| 2 | $AXSM | Axsome Therapeutics, Inc. | $6.9M | 7.0% | NEW | 36.6 |
| 3 | $PRAXPUT | Praxis Precision Medicines, Inc. | $6.6M | — | NEW | — |
| 4 | $XERS | Xeris Biopharma Holdings, Inc. | $5.9M | 6.0% | +28% | 45.5 |
| 5 | $KALV | KalVista Pharmaceuticals, Inc. | $5.6M | 5.6% | NEW | 25.9 |
| 6 | $FOLD | AMICUS THERAPEUTICS, INC. | $5.3M | 5.4% | +3% | 44.2 |
| 7 | $BMRN | BIOMARIN PHARMACEUTICAL INC | $4.6M | 4.7% | -18% | 74.1 |
| 8 | $VSTM | Verastem, Inc. | $4.3M | 4.4% | +204% | 40.8 |
| 9 | $RARE | Ultragenyx Pharmaceutical Inc. | $3.7M | 3.7% | +249% | 31 |
| 10 | $ARWR | ARROWHEAD PHARMACEUTICALS, INC. | $3.5M | 3.5% | NEW | 74.4 |
| 11 |  $PCVX | Vaxcyte, Inc. | $3.3M | 3.4% | +15% | — |
| 12 |  $VERA | Vera Therapeutics, Inc. | $3.3M | 3.3% | NEW | — |
| 13 |  $TVTX | Travere Therapeutics, Inc. | $3.3M | 3.3% | NEW | 39.2 |
| 14 |  $MLTX | MoonLake Immunotherapeutics | $3.2M | 3.3% | NEW | — |
| 15 |  $ZNTL | Zentalis Pharmaceuticals, Inc. | $2.9M | 2.9% | -7% | — |
| 16 |  $SRRK | Scholar Rock Holding Corp | $2.8M | 2.9% | NEW | — |
| 17 |  $ACAD | ACADIA PHARMACEUTICALS INC | $2.7M | 2.8% | -23% | 69.8 |
| 18 |  $ARDX | ARDELYX, INC. | $2.7M | 2.7% | NEW | 35.3 |
| 19 |  $MLYS | Mineralys Therapeutics, Inc. | $2.2M | 2.2% | NEW | — |
| 20 |  $GMAB | GENMAB A/S | $2.2M | 2.2% | +17% | — |
| 21 |  $DBVT | DBV Technologies S.A. | $2.1M | 2.2% | NEW | 6.1 |
| 22 |  $CPRX | CATALYST PHARMACEUTICALS, INC. | $2.0M | 2.0% | NEW | 78.7 |
| 23 |  $SION | Sionna Therapeutics, Inc. | $2.0M | 2.0% | NEW | — |
| 24 |  $CTNM | Contineum Therapeutics, Inc. | $1.9M | 1.9% | NEW | — |
| 25 |  $ALNY | ALNYLAM PHARMACEUTICALS, INC. | $1.7M | 1.7% | NEW | 60.9 |
| 26 |  $LGND | LIGAND PHARMACEUTICALS INC | $1.6M | 1.6% | NEW | 66 |
| 27 |  $EWTX | Edgewise Therapeutics, Inc. | $1.5M | 1.6% | -15% | — |
| 28 |  $IMTX | Immatics N.V. | $1.5M | 1.5% | +92% | — |
| 29 |  $LXRX | LEXICON PHARMACEUTICALS, INC. | $1.4M | 1.4% | +3% | 33.1 |
| 30 |  $BEAM | Beam Therapeutics Inc. | $1.4M | 1.4% | +15% | 12.1 |
| 31 |  $ORIC | Oric Pharmaceuticals, Inc. | $1.3M | 1.3% | -36% | — |
| 32 |  $NAMS | NewAmsterdam Pharma Co N.V. | $1.2M | 1.2% | +23% | — |
| 33 |  $ANNX | Annexon, Inc. | $965,345 | 1.0% | -77% | — |
| 34 |  $IDYA | IDEAYA Biosciences, Inc. | $819,672 | 0.8% | NEW | 10.5 |
| 35 |  $SLN | Silence Therapeutics plc | $740,435 | 0.8% | -41% | — |
| 36 |  $PTCT | PTC THERAPEUTICS, INC. | $698,333 | 0.7% | -72% | 80 |
| 37 |  $GOSS | Gossamer Bio, Inc. | $269,370 | 0.3% | NEW | 27.1 |
New Positions (18)
$AXSM Axsome Therapeutics, Inc.$6.9M$PRAXPUT Praxis Precision Medicines, Inc.$6.6M$KALV KalVista Pharmaceuticals, Inc.$5.6M$ARWR ARROWHEAD PHARMACEUTICALS, INC.$3.5M$VERA Vera Therapeutics, Inc.$3.3M$TVTX Travere Therapeutics, Inc.$3.3M$MLTX MoonLake Immunotherapeutics$3.2M$SRRK Scholar Rock Holding Corp$2.8M$ARDX ARDELYX, INC.$2.7M$MLYS Mineralys Therapeutics, Inc.$2.2M$DBVT DBV Technologies S.A.$2.1M$CPRX CATALYST PHARMACEUTICALS, INC.$2.0M$SION Sionna Therapeutics, Inc.$2.0M$CTNM Contineum Therapeutics, Inc.$1.9M$ALNY ALNYLAM PHARMACEUTICALS, INC.$1.7MExited Positions (19)
$NUVB Nuvation Bio Inc.
$BBIO BridgeBio Pharma, Inc.
$UTHR UNITED THERAPEUTICS Corp
$BCRX BIOCRYST PHARMACEUTICALS INC
$SNDX Syndax Pharmaceuticals Inc
$TARS Tarsus Pharmaceuticals, Inc.
$APOG APOGEE ENTERPRISES, INC.
$INSM INSMED Inc
$CORTCALL CORCEPT THERAPEUTICS INC
$APLS Apellis Pharmaceuticals, Inc.
$DNLI Denali Therapeutics Inc.
$ASND Ascendis Pharma A/S
$BHVN Biohaven Ltd.
$DNTH Dianthus Therapeutics, Inc. /DE/
$NKTR NEKTAR THERAPEUTICSBrowse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
Available Analysis
13F Pro tracks comprehensive institutional data for Ishara Investments LP including:
Track Ishara Investments LP's Full Portfolio
See every holding, quarter-over-quarter changes, sector allocation, and accumulation patterns for Ishara Investments LP and 8,700+ other institutional investors.
Free tier includes full 13F search and fund profiles. Pro starts at $6.67/mo (billed annually).
AI-Powered Hedge Fund Analysis: Ishara Investments LP
13F Pro is an AI hedge fund tracker and stock research platform. For Ishara Investments LP (SEC CIK: 2111609), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in Ishara Investments LP's portfolio is scored on a 32-signal AI quality ranking (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.